Table 3.
CONUT scores and some clinicopathological factors are correlated.
| Total | CL group, n (%) |
CH group, n (%) |
χ² | P value | |
|---|---|---|---|---|---|
| Age | 0.08 | 0.78 | |||
| <60.5 | 607 (77.3%) | 314 (77.72%) | 293 (76.90%) | ||
| ≥60.5 | 178 (22.7%) | 90 (22.28%) | 88 (23.10%) | ||
| BMI (kg/m2) | 8.07 | 0.00 | |||
| <20.0 | 33 (4.2%) | 9 (2.23%) | 24 (6.30%) | ||
| ≥20.0 | 752 (95.8%) | 395 (97.77%) | 357 (93.70%) | ||
| Menopause | 1.09 | 0.30 | |||
| no | 319 (40.6%) | 157 (38.86%) | 162 (42.52%) | ||
| yes | 466 (59.4%) | 247 (61.14%) | 219 (57.48%) | ||
| Relapse | 1.02 | 0.31 | |||
| no | 774 (98.6%) | 400 (99.01%) | 374 (98.16%) | ||
| yes | 11 (1.4%) | 4 (0.99%) | 7 (1.84%) | ||
| PNI | 87.73 | 0.00 | |||
| <52.83 | 478 (60.9%) | 182 (45.05%) | 296 (77.69%) | ||
| ≥52.8 | 307 (39.1%) | 222 (54.95%) | 85 (22.31%) | ||
| NLR | 44.03 | 0.00 | |||
| <1.9 | 299 (38.1%) | 199 (49.26%) | 100 (26.25%) | ||
| ≥1.9 | 486 (61.9%) | 205 (50.74%) | 281 (73.75%) | ||
| PLR | 93.59 | 0.00 | |||
| <175.0 | 627 (79.9%) | 377 (93.32%) | 250 (65.62%) | ||
| ≥175.0 | 158 (20.1%) | 27 (6.68%) | 131 (34.38%) | ||
| LMR | 49.36 | 0.00 | |||
| <6.45 | 452 (57.6%) | 184 (45.54%) | 268 (70.34%) | ||
| ≥6.45 | 333 (42.4%) | 220 (54.46%) | 113 (29.66%) | ||
| CA199 (U/ml) | 0.48 | 0.82 | |||
| <27 | 351 (67.5%) | 175 (67.05%) | 176 (67.95%) | ||
| ≥27 | 169 (32.5%) | 86 (32.95%) | 83 (32.05%) | ||
| CA125 (U/ml) | 1.52 | 0.22 | |||
| <35 | 516 (85.7%) | 271 (87.42%) | 245 (83.90%) | ||
| ≥35 | 86 (14.3%) | 39 (12.58%) | 47 (16.10%) | ||
| CEA (ng/L) | 0.71 | 0.40 | |||
| <5 | 513 (98.8%) | 260 (99.24%) | 253 (98.44%) | ||
| ≥5 | 6 (1.2%) | 2 (0.76%) | 4 (1.56%) | ||
| Pathological classification | 0.26 | 0.61 | |||
| type I | 719 (91.6%) | 372 (92.08%) | 347 (91.08%) | ||
| type II | 66 (8.4%) | 32 (7.92%) | 34 (8.92%) | ||
| Surgical staging | 6.63 | 0.09 | |||
| I | 607 (77.3%) | 321 (79.45%) | 286 (75.07%) | ||
| II | 98 (12.5%) | 46 (11.39%) | 52 (13.65%) | ||
| III | 63 (8.0%) | 33 (8.17%) | 30 (7.87%) | ||
| IV | 17 (2.2%) | 4 (0.99%) | 13 (3.41%) | ||
| Degree of differentiation | 7.46 | 0.02 | |||
| G1 | 437 (55.7%) | 243 (60.15%) | 194 (50.92%) | ||
| G2 | 263 (33.5%) | 125 (30.94%) | 138 (36.22%) | ||
| G3 | 85 (10.8%) | 36 (8.91%) | 49 (12.86%) | ||
| Lymphatic vascular space infiltration | 1.69 | 0.19 | |||
| no | 613 (78.1%) | 323 (79.95%) | 290 (76.12%) | ||
| yes | 172 (21.9%) | 81 (20.05%) | 91 (23.88%) | ||
| Parastatal infiltration | 1.57 | 0.21 | |||
| no | 753 (95.9%) | 391 (96.78%) | 362 (95.01%) | ||
| yes | 32 (4.1%) | 13 (3.22%) | 19 (4.99%) | ||
| Infiltration of muscle layer | 5.99 | 0.01 | |||
| < 1/2 | 585 (74.5%) | 316 (78.22%) | 269 (70.60%) | ||
| ≥1/2 | 200 (25.5%) | 88 (21.78%) | 112 (29.40%) | ||
| Cervical interstitial infiltration | 1.33 | 0.25 | |||
| no | 673 | 352(87.13%) | 321 (84.25%) | ||
| yes | 112 | 52 (12.87%) | 60 (15.75%) | ||
| Aortic lymph node metastasis | 0.15 | 0.70 | |||
| no | 772 (98.3%) | 398 (98.51%) | 374 (98.16%) | ||
| yes | 13 (1.7%) | 6 (1.49%) | 7 (1.84%) | ||
| Pelvic lymph node metastasis | 0.34 | 0.85 | |||
| no | 747 (95.2%) | 385 (95.30%) | 362 (95.01%) | ||
| yes | 38 (4.8%) | 19 (4.70%) | 19 (4.99%) |
CH, CONUT-high; CL, CONUT-low; BMI, body mass index; PNI, prognostic nutrition index; NLR, neutrophil/lymphocyte ratio; PLR=platelet/lymphocyte ratio; LMR, lymphocyte to monocyte ratio; CA199, cancer antigen 199; CA125, cancer antigen 125; CEA, Carcinoembryonic Antigen. Bold and highlighted for significant p-values.